Matinas Biopharma Revenue, Profits - MTNB Quarterly Income Statement

Add to My Stocks
$0.41 $0.01 (2.38%) MTNB stock closing price Sep 19, 2018 (Closing)

Fundamental analysis of MTNB stock involves analyzing its financial statements, apart from checking the Matinas Biopharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. Like any other income statement, the MTNB income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of 0 when compared to the same period in the past. The operating expenses as shown in the Matinas Biopharma profit and loss statement for 2018 Q2 total to $3.49M. This line item shows that the operating expenses has decreased compared with last year. Also check: Matinas Biopharma assets and Matinas Biopharma free cash flow.

View and download details of revenue and profits for Matinas Biopharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Matinas Biopharma Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Matinas Biopharma Gross Profit
----------
Research & Development Expense1.52M2.19M2.31M2.01M2.31M2.38M1.55M---
Selling General & Admin Expense1.97M1.95M2.39M1.44M1.7M2.11M1.03M--1.31M
Income Before Depreciation Depletion Amortization-3.4M-4.12M-4.65M-3.4M-3.97M-4.48M-2.57M-1.83M-1.62M-2.23M
Depreciation Depletion Amortization----------
Non Operating Income-0.01M-----0.01M----0.01M
Interest Expense----------
Matinas Biopharma Pretax Income
-3.41M-4.11M-4M-3.39M-3.96M-4.49M-1.9M-1.83M-1.62M-2.24M
Provision for Income Taxes---0.35M-------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-3.41M-4.11M-3.63M-3.4M-3.97M-21.24M-1.89M-1.84M-1.62M-2.25M
Extraordinary Items & Discontinued Operations----------
Matinas Biopharma Profit/ Loss (Net Income)
-3.41M-4.11M-3.63M-3.4M-3.97M-21.24M-1.89M-1.84M-1.62M-2.25M
Average Shares used to compute Diluted EPS94.04M93.54M120.93M92.22M91.61M84.6M58.46M57.63M57.59M57.29M
Average Shares used to compute Basic EPS94.04M93.54M120.93M92.22M91.61M84.6M58.46M57.63M57.59M57.29M
Income Before Nonrecurring Items-3.41M-4.11M-3.63M-3.4M-3.97M-21.24M-1.89M-1.84M-1.62M-2.25M
Income from Nonrecurring Items----------
Matinas Biopharma Earnings Per Share Basic Net
-0.04-0.05-0.03-0.04-0.04-0.25-0.03-0.11-0.03-0.04
Matinas Biopharma Earnings Per Share Diluted Net
-0.04-0.05-0.03-0.04-0.04-0.25-0.03-0.11-0.03-0.04
EPS Diluted Before Nonrecurring Items-0.04-0.05-0.03-0.04-0.04-0.25-0.03-0.11-0.03-0.04
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Matinas Biopharma stock analysis are:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Matinas Biopharma revenue chart, implies that the company is growing. It has not been the case with Matinas Biopharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-3.41M for Matinas Biopharma for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the MTNB income statement, one can check the Matinas Biopharma historical stock prices to check how the price has moved with time.

Matinas Biopharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
173.12
Dividend Yield
0%